On 31 July, Viatris will close the flagship Morgantown plant that has for years been grappling with US Food and Drug Administration compliance issues that ultimately resulted in a warning letter from the agency. However, the firm has revealed to Generics Bulletin that it is still exploring “viable alternatives for the site outside of the company’s network.”
With Mylan – now part of Viatris – having pledged in mid-2018 to implement a “robust improvement plan” for the Chestnut Ridge oral solid dose manufacturing facility at Morgantown, following an extensive Form 483 issued by the FDA highlighting 13 observations of deficiencies (Also see "Mylan to improve Morgantown" - Generics